Skip to main content
Top
Published in: BMC Health Services Research 1/2012

Open Access 01-12-2012 | Research article

National Essential Medicines List and policy practice: A case study of China’s health care reform

Published in: BMC Health Services Research | Issue 1/2012

Login to get access

Abstract

Background

In 2009, China implemented the national essential medicines system by enacting the National Essential Medicines List 2009. According to the policy of this system, primary health care institutions can only stock and use essential medicines on the prescribed List. Meanwhile, each province can choose to make its own list of supplemented medicines. The goal of the study is to provide suggestions for emerging problems and identify future policy-making trends.

Methods

In this study, we statistically analyzed the National Essential Medicines List 2009 and lists of supplemented medicines of all 29 provinces. We also examined the rationality of such medicines based on the DELPHI method and literature review, after which we studied the provincial supplements in relation to the national essential medicines system.

Results

We demonstrated that the National Essential Medicines List 2009 provides a comprehensive coverage of diseases as well as reasonable varieties of drugs for their treatment. The average number of supplemented medicines in 29 provinces is 207, with each medicine included in 2.9 provincial lists on average. Only 2.6% supplemented medicines are included by more than half of the provinces (>15), indicating great regional variance. Among the 32 most frequently supplemented medicines, only 18 meet the selection principles, including two with strict usage restrictions.

Conclusion

The structure and selection of the National Essential Medicines List 2009 are relatively reasonable. The main problems, however, include the excessive and non-scientific selection of medicines on the supplemented medicines list. The function of the provincial lists of supplemented medicines has not been achieved, which has influenced the effectiveness of the national essential medicines system in China.
Literature
1.
go back to reference World Health Organization: World Medicines Situation. 2004, Geneva: WHO Headquarters World Health Organization: World Medicines Situation. 2004, Geneva: WHO Headquarters
2.
go back to reference Quick JD: Essential medicines twenty-five years on: closing the access gap. Health Policy Plan. 2003, 18 (1): 1-3. 10.1093/heapol/18.1.1.CrossRefPubMed Quick JD: Essential medicines twenty-five years on: closing the access gap. Health Policy Plan. 2003, 18 (1): 1-3. 10.1093/heapol/18.1.1.CrossRefPubMed
3.
go back to reference Che MF, Han BS: Implementing of National Essential Medicines List in China. Chinese Pharmaceutical Affairs. 2000, 14 (1): 10-21. Che MF, Han BS: Implementing of National Essential Medicines List in China. Chinese Pharmaceutical Affairs. 2000, 14 (1): 10-21.
4.
go back to reference Sun Q, Santoro MA: Qingyue Meng Caitlin Liu and Karen Eggleston. Pharmaceutical Policy In China Health Affairs. 2008, 27 (4): 1042-1050.CrossRefPubMed Sun Q, Santoro MA: Qingyue Meng Caitlin Liu and Karen Eggleston. Pharmaceutical Policy In China Health Affairs. 2008, 27 (4): 1042-1050.CrossRefPubMed
5.
go back to reference Zhan SK, Tang SL, Guo YD, Bloom G: Drug prescribing in rural health facilities in China: implications for service quality and cost. Trop Doct. 1998, 28 (1): 42-48.PubMed Zhan SK, Tang SL, Guo YD, Bloom G: Drug prescribing in rural health facilities in China: implications for service quality and cost. Trop Doct. 1998, 28 (1): 42-48.PubMed
6.
go back to reference Dong H, Bogg L, Wang K, Rehnberg C, Diwan V: A description of outpatient drug use in rural China: evidence of differences due to insurance coverage. J Health Plann Manage. 1999, 14 (1): 41-56. 10.1002/(SICI)1099-1751(199901/03)14:1<41::AID-HPM529>3.0.CO;2-Q.CrossRef Dong H, Bogg L, Wang K, Rehnberg C, Diwan V: A description of outpatient drug use in rural China: evidence of differences due to insurance coverage. J Health Plann Manage. 1999, 14 (1): 41-56. 10.1002/(SICI)1099-1751(199901/03)14:1<41::AID-HPM529>3.0.CO;2-Q.CrossRef
7.
go back to reference Zhang Y, Harvey K: Rational antibiotic use in China: lessons learnt through introducing surgeons to Australian guidelines. Aust New Zealand Health Policy. 2006, 30 (3): 5.CrossRef Zhang Y, Harvey K: Rational antibiotic use in China: lessons learnt through introducing surgeons to Australian guidelines. Aust New Zealand Health Policy. 2006, 30 (3): 5.CrossRef
8.
go back to reference Chen W, Tang S, Sun J, Ross-Degnan D, Wagner AK: Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res. 2010, 17 (10): 211.CrossRef Chen W, Tang S, Sun J, Ross-Degnan D, Wagner AK: Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res. 2010, 17 (10): 211.CrossRef
10.
go back to reference Laing R, Waning B, Gray A, et al: 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003, 361 (9370): 1723-1729. 10.1016/S0140-6736(03)13375-2.CrossRefPubMed Laing R, Waning B, Gray A, et al: 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003, 361 (9370): 1723-1729. 10.1016/S0140-6736(03)13375-2.CrossRefPubMed
12.
go back to reference Xiao AL, Jing CM, Yan L, et al: Exploration on the Adjustment Principle of National Essential Medicines List. Chinese Journal of Pharmacoepidemiology. 2005, 14 (5): 300-302. Xiao AL, Jing CM, Yan L, et al: Exploration on the Adjustment Principle of National Essential Medicines List. Chinese Journal of Pharmacoepidemiology. 2005, 14 (5): 300-302.
13.
go back to reference Jing P, Qicheng J: National Essential Drugs List rationality analysis. Chinese Health Service Management. 2011, 1: 38-39. Jing P, Qicheng J: National Essential Drugs List rationality analysis. Chinese Health Service Management. 2011, 1: 38-39.
14.
go back to reference Linli Z, Chuan Z, Yi L, Li P: The comparative analysis between the 2009 edition of Essential Drugs List (primary) and WHO201 O version of Essential Medicines for Children demonstration directory. Inquiry with Medicine. 2010, 10 (9): 1027-1036. Linli Z, Chuan Z, Yi L, Li P: The comparative analysis between the 2009 edition of Essential Drugs List (primary) and WHO201 O version of Essential Medicines for Children demonstration directory. Inquiry with Medicine. 2010, 10 (9): 1027-1036.
15.
go back to reference Zhang Yanling H, Xiaoxu FR: Comparison of the efficacy of the suspensions, and suppositories of paracetamol for fever in children. Pediatrics. 2005, 20 (9): 867-868. Zhang Yanling H, Xiaoxu FR: Comparison of the efficacy of the suspensions, and suppositories of paracetamol for fever in children. Pediatrics. 2005, 20 (9): 867-868.
16.
go back to reference Jie W, Xiaoling W: Chinese pediatric drug analysis. Chinese Journal of Medical Practice. 2006, 5 (9): 1001-1002. Jie W, Xiaoling W: Chinese pediatric drug analysis. Chinese Journal of Medical Practice. 2006, 5 (9): 1001-1002.
18.
go back to reference Chan TY, Chan AW: Aminopyrine-induced blood dyscrasias–still a problem in many parts of the world. Pharmacoepidemiol Drug Saf. 1996, 5 (4): 215-219. 10.1002/(SICI)1099-1557(199607)5:4<215::AID-PDS208>3.0.CO;2-5.CrossRefPubMed Chan TY, Chan AW: Aminopyrine-induced blood dyscrasias–still a problem in many parts of the world. Pharmacoepidemiol Drug Saf. 1996, 5 (4): 215-219. 10.1002/(SICI)1099-1557(199607)5:4<215::AID-PDS208>3.0.CO;2-5.CrossRefPubMed
19.
go back to reference Ries CA, Sahud MA: Agranulocytosis caused by Chinese herbal medicines. Dangers of medications containing aminopyrine and phenylbutazone. JAMA. 1975, 231 (4): 352-355. 10.1001/jama.1975.03240160016019.CrossRefPubMed Ries CA, Sahud MA: Agranulocytosis caused by Chinese herbal medicines. Dangers of medications containing aminopyrine and phenylbutazone. JAMA. 1975, 231 (4): 352-355. 10.1001/jama.1975.03240160016019.CrossRefPubMed
20.
go back to reference Freston JW: Cimetidine: II Adverse reactions and patterns of use. Ann Intern Med. 1982, 97 (5): 728-734.CrossRefPubMed Freston JW: Cimetidine: II Adverse reactions and patterns of use. Ann Intern Med. 1982, 97 (5): 728-734.CrossRefPubMed
21.
go back to reference Kevin L, Low DE, Rogers AG: Cimetidine-induced fever. Can Med Assoc J. 1984, 130 (12): 1580. Kevin L, Low DE, Rogers AG: Cimetidine-induced fever. Can Med Assoc J. 1984, 130 (12): 1580.
Metadata
Title
National Essential Medicines List and policy practice: A case study of China’s health care reform
Publication date
01-12-2012
Published in
BMC Health Services Research / Issue 1/2012
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/1472-6963-12-401

Other articles of this Issue 1/2012

BMC Health Services Research 1/2012 Go to the issue